PepGene Inc United States

Cancer Immunotherapy development
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
Tenghui Chen
CTO 

Personalis United States

Personalis, Inc. headquartered in Menlo Park California, USA, Was established in 2011 as a Stanford University spin-out by a team of internationally-renown Next Generation Sequencing (NGS) thought leaders to provide advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and cancer immunotherapies by providing more comprehensive molecular data bout each patient’s cancer and immune response. The Personalis ImmunoID NeXT Platform TM is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample The Personalis Clinical Laboratory in Menlo Park, Califonria is GxP aligned as well as CLIA’88-certified and CAP-accredited.

On 10 June 2020 Personalis, Inc announced a partnership with Berry Genomics with plans to expand operations in PRC with a wholly-owned subsidiary in Shanghai. Berry will provide sequencing services and local support to Personalis operation in Shanghai. Personalis, Inc was granted approval for a business license for Shanghai Personalis Biotechnology Co, LTD on 15 October 2020. The expansion to China includes buildout of a laboratory operation for local customers to use its ImmunoID Next Platform, a commercial team to support local customers and general and administrative functions.

Company Size (Fulltime employees)
Year of foundation
2011
Partnering Objectives
Please specify your partnering goal
We are looking for partnership opportunities with with local therapeutics and diagnostic companies in China
Headquartner in China
Biotech/Pharma Category
Medtech Category
Medtech Information 1
NeXT Dx
Your Research Tool and Service name
ImmunoID NeXT
Service Description
ImmunoID NeXT is the best in class NGS based IO profiling platform.
Target client type
pharma companies
Dr. Howard Pan
Director of Business Development 
Functionality

Pfizer China

Pfizer Inc. is an American multinational pharmaceutical corporation. One of the world's largest pharmaceutical companies.
Company Size (Fulltime employees)
Please specify your partnering goal
Looking for innovative products and companies with innovative pipeline assets.
Headquartner in China
Biotech/Pharma Category
Dr. Feng Bian
Dr. Feng Bian
Sr Director/Emerging Science Lead-China 
林 王
医学经理 
Ms. ying wu
Manager 
Functionality
Dr. Ying Niu
China Search and Evaluation Lead 
Functionality

Polaris Strategic Partners United States

An innovative company to partner with emerging biotech companies in drug clinical development and commercialization through United States and China alliance of drug development.
Jane Fang
CEO 

Qilu Pharmaceutical North America China

Located in Jinan, Qilu Pharmaceutical is one of the leading pharmaceutical companies in China. It focuses on developing, manufacturing and marketing of generic drugs and active pharmaceutical ingredients in the therapeutic areas of Oncology, Cerebrovascular & Cardiovascular, Infections, Psychological&Neurological System, Respiratory System, Ophthalmological Diseases, etc. Qilu has more than 8000 employees, 70% of which have the college degree or above.

Qilu pharmaceutical has always been sticking to the innovative development strategy. Guided by the market demand and the product innovation, Qilu has established extensive cooperation with domestic and foreign partners on a series of R&D projects. Qilu pays high attention to the introduction and cultivation of talents and has built a highly qualified R&D team with professional and efficient R&D capabilities, More than 100 national new drugs have been successfully developed, which constitutes the reasonable production line for the future development of Qilu. A number of technological achievements have obtained the national and provincial scientific & technological progress awards and created good social benefit.

Qilu Pharmaceutical has eight manufacturing sites covering an area of more than 2800,000 ㎡for finished dosage forms, chemical synthesis, genetic-engineering, fermentation, etc. The modern workshops are located in the manufacturing sites where the automatic production lines, key equipments and analytical instruments are imported from the leading suppliers all over the world. Now Qilu Pharmaceutical has been one of the leading global suppliers of Antibiotic APIs and Oncology APIs with huge capacity and good quality.

Qilu pharmaceutical has always been committing itself to providing the high-quality products to the patients and the society. Thanks to the integrated and stringent system of quality control and quality assurance, the company has been the leader of cGMP implementation in China. Its non-sterile APIs (fermentation and chemical synthesis), sterile APIs and comprehensive finished dosages have been respectively approved by USFDA, European Directorate for the Quality of Medicines (EDQM), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, Medicines Control Council (MCC) of South Africa, and some other national competent authorities.

Qilu Pharmaceutical has an integrated product structure and value chain with over 160 launched products. The company has established a comprehensive domestic and overseas sales network. The global presence has covered North America, Europe, CIS countries, South America, Asia, South Africa and Middle East. The valuable brand of the company has been well built with the quality products and good services.
Dr. Jun Sun
VP, Business Development 
Functionality

Reistone Biopharma China

一家源于China的处于临床阶段的生物技术公司,聚焦于研发自身免疫疾病领域的创新药,为China和全世界患者提供未满足的临床用药。

Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
License in/out
Headquartner in China
Biotech/Pharma Asset Stage
Yufeng Wang
Yufeng Wang
Senior Director BD 

RemeGen China

RemeGen is committed to the discovery, development and commercialization of innovative and differentiated biological drugs. We strive to continuously create value through our clinical studies to develop products that meet the unmet clinical needs. We aim to become a global leader in the bio-pharmaceutical industry
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
贵 黄
投资副总裁 

Rius Medical UG (Haftungsbeschränkt) Germany

About Rius Medical: Rius Medical is designing and developing a new generation of Commercial cell therapies positioned at the crossroads of two high-potential programs: (1.) genetically engineering red blood cells for an entirely new class of cellular medicines and (2.) potent NK-cell therapy products. Due to their mechanism of action, engineered red blood cells demonstrated treatments for wide range of patients from starving cancer cells to targeting autoimmune diseases. Building on exceptional progress in cell therapies, Rius Medical is in a unique position to offer Third-Generation red blood cells for drug delivery that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes! Furthermore, harnessing the unique power of natural killer (NK) cells enables the treatment of cancer and infectious diseases such as Influenza virus or SARS-Coronavirus (i.e. COVID-19 pandemic). That’s right, NK-cells as vaccine delivery NOT for antibodies but for “memory T cells” activation!
Company Size (Fulltime employees)
Year of foundation
2016
Partnering Objectives
Please specify your partnering goal
Partnering goal is to improve life and generate substantial economic return
Headquartner in China
Mr. Denis Demarais
Founder and CEO 
Functionality

SAPA-DC United States

NGO
Website:
Www.sapadc.org
Headquartner in China
Biotech/Pharma Category
Vince Deng
President